What Is ELV Fair Value?
Elevance Health (ELV) fair value estimate using multiple valuation models, updated daily.
As of July 16, 2026, Elevance Health (ELV) has a composite fair value estimate of $329.53 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $390.33, suggesting the stock is overvalued by 15.6%.
Data as of July 16, 2026 (today)
Composite Fair Value
Overvalued4 of 4 models$329.53
vs. current price of $390.33(-15.6%)
How Is ELV Fair Value Calculated?
Four independent models estimate what ELV is worth. Each uses different inputs and assumptions. The composite blends them by weight.
ELV Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$382.08
-2.1%Fair Value
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$112.16
-71.3%Overvalued
Inputs used
ELV Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$350.76
-10.1%Fair Value
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$270.74
-30.6%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $390.33 is 2.1% above this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $4.38B | $4.09B |
| Year 2 | $4.47B | $3.90B |
| Year 3 | $4.56B | $3.72B |
| Year 4 | $4.65B | $3.54B |
| Year 5 | $4.75B | $3.37B |
| Year 6 | $4.84B | $3.21B |
| Year 7 | $4.94B | $3.06B |
| Year 8 | $5.04B | $2.91B |
| Year 9 | $5.14B | $2.78B |
| Year 10 | $5.24B | $2.64B |
| Terminal Value | $117.26B | $59.16B |
What Are ELV's Key Financial Metrics?
Earnings & Growth
Current Price
$390.33
EPS (TTM)
$21.59
Forward P/E
13.1
Profit Margin
2.6%
Cash & Balance Sheet
Free Cash Flow
4.3B
EBITDA
8.5B
Book Value
$201.97
Total Debt
31.8B
What Do Analysts Say About ELV?
Low
$364.00
Average
$447.62
High
$498.00
Upside
+14.7%
ELV Fair Value FAQ
What is the fair value of ELV?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), ELV's estimated fair value is $329.53. The stock is currently trading at $390.33, which makes it overvalued by our analysis.
How is ELV's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is ELV overvalued or undervalued?
Based on our analysis, ELV is overvalued. The current price of $390.33 is 15.6% above our estimated fair value of $329.53.
What do Wall Street analysts say about ELV?
21 analysts cover Elevance Health with a consensus rating of "Buy." The average price target is $447.62, ranging from $364.00 to $498.00. This implies 14.7% upside from the current price.